![](/img/cover-not-exists.png)
Durability of alirocumab effect: Data from an open-label extension to the ODYSSEY program for patients with heterozygous familial hypercholesterolemia
Farnier, M., Hovingh, G.K., Langset, G., Dufour, R., Baccara-Dinet, M., Din-Bell, C., Manvelian, G., Guyton, J.R.Volume:
78
Journal:
Annales d'Endocrinologie
DOI:
10.1016/j.ando.2017.07.234
Date:
September, 2017
File:
PDF, 200 KB
2017